ADCT 8-K 2026-11-09

ADC Therapeutics SA (ADCT) 8-K dated 2026-11-09 — accession 0001628280-26-071899.

ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.

ADC Therapeutics SA filed a 8-K on 2026-11-09. Accession 0001628280-26-071899.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ADCT revenue for 2025-12-31 was $81.4M. Net income was -$142.6M. Revenue was up 14.9% from 2024-12-31 to 2025-12-31. ADCT currently screens at market cap $141.2M.

Not investment advice. The ADCT SEC hub lists recent forms. The stock page is the research view.